{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:57:37Z","timestamp":1781672257509,"version":"3.54.5"},"reference-count":273,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma and chronic lymphocytic leukemia are among the most common hematological tumors. Although first-line therapies are initially effective, their clinical benefit is frequently compromised by the emergence of acquired drug resistance. In recent years, novel immunotherapies such as checkpoint inhibitors, chimeric antigen receptor T-cells, and bispecific antibodies are showing promising results in preclinical studies, achieving high rates of response and remission in some cases. However, despite these advances, durable responses are not achieved in all patients, and treatment failure, toxicity and resistance remain major clinical challenges. In this review, we have comprehensively examined current strategies aimed at optimizing immunotherapy efficacy through rational combination approaches including novel immunotherapies with established standard-of-care agents as well as emerging treatments. Moreover, we have explored the growing evidence supporting the role of the gut microbiota in both B-cell malignancies, focusing on its influence on disease biology and modulation of immunotherapeutic responses to further improve patient outcomes. Finally, we have addressed the current challenges and future perspectives in the field of immunotherapy in both diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1805129","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:50:50Z","timestamp":1781671850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation"],"prefix":"10.3389","volume":"17","author":[{"given":"Andrea","family":"Adrados","sequence":"first","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"P\u00e9rez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garrote-de-Barros","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]},{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]},{"name":"Department of Medicine, Faculty of Medicine, Complutense University of Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Linares","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]},{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12OCNIO","place":["Madrid, Spain"]},{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092266","article-title":"Advances and perspectives in the treatment of B-cell Malignancies","volume":"13","author":"Cuenca","year":"2021","journal-title":"Cancers"},{"key":"B2","volume-title":"The immune system","author":"Parham","year":"2009"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094644","article-title":"Characterization of human B cell hematological Malignancies using protein-based approaches","volume":"25","author":"Jim\u00e9nez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities\u2014evolution in diagnosis and classification","volume":"482","author":"Fend","year":"2023","journal-title":"Virchows Arch"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"aaaaaaa Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07547.x","article-title":"Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols","volume":"145","author":"Nair","year":"2009","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study","volume":"1","author":"Kyle","year":"2014","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(10)70008-6","article-title":"Role of new treatment approaches in defining treatment goals in multiple myeloma \u2013 the ultimate goal is extended survival","volume":"36","author":"Durie","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035220","article-title":"Chronic lymphocytic leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01852-w","article-title":"Survival in hematological Malignancies in the Nordic countries through a half century with correlation to treatment","volume":"37","author":"Hemminki","year":"2023","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03460-y","article-title":"Chronic lymphocytic leukaemia\/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation","volume":"482","author":"Sander","year":"2023","journal-title":"Virchows Arch Int J Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236000","article-title":"Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies","volume":"105","author":"Delgado","year":"2020","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)\u2014a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70196","article-title":"Immune checkpoint molecules: a review on pathways and immunotherapy implications","volume":"13","author":"Rezazadeh\u2010Gavgani","year":"2025","journal-title":"Immun Inflammation Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"TPS8051","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8051","article-title":"Phase 1 study to evaluate the safety and efficacy of immunotherapy with tremelimumab and durvalumab in multiple myeloma patients receiving high dose chemotherapy and autologous stem cell transplant (HDT\/ASCT) + peripheral blood lymphocyte (PBL) reinfusion","volume":"35","author":"Lesokhin","year":"2017","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123615","article-title":"Pembrolizumab as consolidation strategy in patients with multiple myeloma: results of the GEM-Pembresid clinical trial","volume":"12","author":"Puig","year":"2020","journal-title":"Cancers"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2023.1244494","article-title":"Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I\/II clinical trial","volume":"2","author":"Abdallah","year":"2023","journal-title":"Front Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5753","article-title":"Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: a phase 1\/2 study","volume":"12","author":"Lesokhin","year":"2023","journal-title":"Cancer Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102452","article-title":"Efficacy and safety of durvalumab combined with daratumumab in daratumumab-refractory multiple myeloma patients","volume":"13","author":"Frerichs","year":"2021","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","first-page":"TPS8053","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8053","article-title":"A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and\/or daratumumab in patients (pts) with multiple myeloma (MM)","volume":"35","author":"Cho","year":"2017","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.clml.2024.08.004","article-title":"The evolving role of checkpoint inhibitors in multiple myeloma","volume":"25","author":"Chakrabarti","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B50","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2023.06.007","article-title":"Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia","volume":"34","author":"Cass","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1592574","article-title":"A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter transformation","volume":"16","author":"Vom Stein","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2023.41.16_suppl.7502","article-title":"Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome","volume":"41","author":"Frustaci","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"biomark Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/caac.21702","article-title":"Critical care management of chimeric antigen receptor T-cell therapy recipients","volume":"72","author":"Shimabukuro-Vornhagen","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900928","article-title":"CAR-T efficacy: is conditioning the key","volume":"133","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-94353-0","article-title":"The EBMT\/EHA CAR-T cell handbook","volume-title":"The EBMT\/EHA CAR-T cell handbook [Internet]","author":"Kr\u00f6ger","year":"2022"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aap9777","article-title":"An immunoproteomic approach to characterize the CAR interactome and signalosome","volume":"12","author":"Ramello","year":"2019","journal-title":"Sci Signal"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112944","article-title":"CAR-T cells immunotherapies for the treatment of acute myeloid leukemia\u2014Recent advances","volume":"15","author":"Zarychta","year":"2023","journal-title":"Cancers"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"blood.2022017415","DOI":"10.1182\/blood.2022017415","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.02.003","article-title":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies","volume":"60","author":"Gea-Banacloche","year":"2023","journal-title":"Semin Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.045","article-title":"CAR-T cells in chronic lymphocytic leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: a phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.320","article-title":"CD19-directed CAR-T therapy for Richter transformation: a CIBMTR analysis","volume":"31","author":"Nadiminti","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2024-200050","article-title":"CD19 CAR-T cell therapy is effective in Richter transformation: a multicenter retrospective analysis by the European Research Initiative on Chronic Lymphocytic Leukemia","volume":"144","author":"Beyar-Katz","year":"2024","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178747","article-title":"Richter transformation in chronic lymphocytic leukemia: current treatment challenges and evolving therapies","volume":"26","author":"Lin","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184550","article-title":"Bispecific antibodies in hematological Malignancies: a scoping review","volume":"15","author":"Omer","year":"2023","journal-title":"Cancers"},{"key":"B84","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1352014","article-title":"Design and engineering of bispecific antibodies: insights and practical considerations","volume":"12","author":"Madsen","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2321635","article-title":"A pivotal decade for bispecific antibodies","volume":"16","author":"Surowka","year":"2024","journal-title":"mAbs"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific antibody use in patients with lymphoma and multiple myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132337","article-title":"Bispecific antibodies for the management of relapsed\/refractory multiple myeloma","volume":"16","author":"Tacchetti","year":"2024","journal-title":"Cancers"},{"key":"B90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D\u2019Souza","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), a BCMA \u00d7 CD3 T-cell engager, in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"HemaSphere"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: a phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2023-173796","article-title":"Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter\u2019s transformation","volume":"142","author":"Cheah","year":"2023","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Carlo\u2010Stella","year":"2023","journal-title":"Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2352-3026(25)00327-8","article-title":"Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b\/2 trial","volume":"13","author":"Kater","year":"2026","journal-title":"Lancet Haematol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/10932607241301699","article-title":"Emerging therapies in multiple myeloma: leveraging immune checkpoint inhibitors for improved outcomes","volume":"33","author":"Mandavkar","year":"2025","journal-title":"Hum Antibodies"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low\u2010dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE\u2010023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br J Haematol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0267","article-title":"PD-1 blockade reinvigorates bone marrow CD8+ T cells from patients with multiple myeloma in the presence of TGF\u03b2 inhibitors","volume":"26","author":"Kwon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114502","article-title":"Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer","volume":"14","author":"Zhou","year":"2022","journal-title":"EMBO Mol Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17448","article-title":"Pembrolizumab combined with carfilzomib and low\u2010dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE\u2010023 study","volume":"194","author":"Moreau","year":"2021","journal-title":"Br J Haematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1323914","article-title":"Immune checkpoint blockade in hematological Malignancies: current state and future potential","volume":"14","author":"Pophali","year":"2024","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.014","article-title":"Nivolumab, pomalidomide, and elotuzumab combination regimens for treatment of relapsed and refractory multiple myeloma: results from the phase 3 CheckMate 602 study","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041195","article-title":"Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma","volume":"9","author":"Franssen","year":"2020","journal-title":"J Clin Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020164","article-title":"PD-L1\/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00878-1","article-title":"Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model","volume":"23","author":"Sokolowska","year":"2022","journal-title":"Clin Exp Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell\u2013inflamed versus non-T cell\u2013inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"viii712","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41541-024-00979-w","article-title":"DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma","volume":"9","author":"Neeli","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101082","article-title":"Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic Malignancies","volume":"74","author":"Huang","year":"2024","journal-title":"Drug Resist Update"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2025.101633","article-title":"Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma","volume":"38","author":"Xu","year":"2025","journal-title":"Best Pract Res Clin Haematol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation \u2014 lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor\u2013redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti\u2013B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12967-024-05772-w","article-title":"BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed\/refractory multiple myeloma","volume":"22","author":"Yan","year":"2024","journal-title":"J Transl Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000184","article-title":"Pomalidomide improves the effectiveness of CAR-T treatment in the relapsed and refractory multiple myeloma or B-cell leukemia\/lymphoma with extramedullary disease","volume":"6","author":"Zhao","year":"2024","journal-title":"Blood Sci"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486","article-title":"Anti\u2010CD19 and anti\u2010BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem\u2010cell transplantation for high\u2010risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27973","article-title":"Developing next generation immunomodulatory drugs and their combinations in multiple myeloma","volume":"12","author":"Thakurta","year":"2021","journal-title":"Oncotarget"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01793-7","article-title":"P-175 improving anti-BCMA CAR-T functionality with novel immunomodulatory agent iberdomide (CC220) in multiple myeloma","volume":"23","author":"Aleman","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1182\/blood-2021-147412","article-title":"KarMMa-7, a phase 1\/2, dose-finding and dose-expansion study of combination therapies with idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy for relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Raje","year":"2021","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2024.42.16_suppl.7505","article-title":"Efficacy and safety of ciltacabtagene autoleucel \u00b1 lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D","volume":"42","author":"Arnulf","year":"2024","journal-title":"J Clin Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03477-9","article-title":"Efficacy\/safety of Cilta-Cel \u00b1 Lenalidomide maintenance in patients with multiple myeloma who had suboptimal response to frontline ASCT: Updated follow-up from CARTITUDE-2 Cohort D","volume":"25","author":"Cohen","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124071","article-title":"Focusing on selinexor for holding and bridging prior to CAR-T in relapsed\/refractory multiple myeloma","volume":"14","author":"Khouri","year":"2025","journal-title":"J Clin Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970364.16259.0e","article-title":"P865: Teclistamab in combination with lenalidomide in previously treated patients with multiple myeloma in the phase 1b multicohort Majestec-2 study","volume":"7","author":"Tan","year":"2023","journal-title":"HemaSphere"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002310","article-title":"Modulation of anti-tumour immunity by XPO1 inhibitors","volume":"6","author":"Fisher","year":"2025","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"B138","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","article-title":"A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"6930","DOI":"10.1182\/blood-2023-190413","article-title":"Sequential administration of selinexor and CAR-T therapy in relapsed\/ refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041316","article-title":"Impact of prior selinexor exposure on outcomes of chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma: an exploratory analysis","volume":"14","author":"Costa","year":"2025","journal-title":"J Clin Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16550","article-title":"Selinexor\u2010based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy","volume":"189","author":"Chari","year":"2020","journal-title":"Br J Haematol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: Results from the Majestec-2 cohort a and Trimm-2 studies","volume":"144","author":"D\u2019Souza","year":"2024","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3390\/cells14060430","article-title":"Selinexor\u2019s immunomodulatory impact in advancing multiple myeloma treatment","volume":"14","author":"Tasbihi","year":"2025","journal-title":"Cells"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1182\/blood-2019-128528","article-title":"AMG 701 potently induces anti-multiple myeloma (MM) functions of T cells and IMiDs further enhance its efficacy to prevent MM relapse in vivo","volume":"134","author":"Cho","year":"2019","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1182\/blood-2025-95","article-title":"Impact of lenalidomide pre-apheresis on markers of T cell fitness and pharmacodynamic biomarkers in newly diagnosed multiple myeloma patients with suboptimal response to autologous stem cell transplantation","volume":"146","author":"Tang","year":"2025","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0075","article-title":"Kinetics of nirogacestat-mediated increases in B-cell maturation antigen on plasma cells inform therapeutic combinations in multiple myeloma","volume":"4","author":"Shearer","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B153","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti\u2013multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: Teclistamab (TEC) + nirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): The phase 1b Majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"},{"key":"B157","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30 single cohort results from Majestec-2: Teclistamab (TEC) in combination with subcutaneous daratumumab (DARA) and lenalidomide (LEN) in patients with multiple myeloma (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"HemaSphere"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2025-367","article-title":"A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a","volume":"146","author":"Manier","year":"2025","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160173","article-title":"MajesTEC-7: A phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065","article-title":"MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)","volume":"41","author":"Grosicki","year":"2023","journal-title":"J Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1200\/JCO.2025.43.16_suppl.7504","article-title":"Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1","volume":"43","author":"Quach","year":"2025","journal-title":"J Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood-2024-210520","article-title":"Efficacy of elranatamab (ELRA) in combination with carfilzomib (CFZ) and dexamethasone (DEX) in the phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"144","author":"Tomasson","year":"2024","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101367","article-title":"Immunomodulatory effect of proteasome inhibitors via the induction of immunogenic cell death in myeloma cells","volume":"16","author":"Matsushita","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7577","article-title":"MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"42","author":"Lesokhin","year":"2024","journal-title":"J Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2025-100","article-title":"Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial","volume":"146","author":"Suvannasankha","year":"2025","journal-title":"Blood"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166854","article-title":"Magnetismm-4: An open label, phase 1b\/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma","volume":"140","author":"Landgren","year":"2022","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8074","article-title":"MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Grosicki","year":"2022","journal-title":"J Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1200\/JCO.2025.43.16_suppl.7513","article-title":"Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial","volume":"43","author":"Manier","year":"2025","journal-title":"J Clin Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + pomalidomide in patients with relapsed\/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"B174","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J Clin Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029360","article-title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","volume":"146","author":"Chari","year":"2025","journal-title":"Blood"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162733","article-title":"MonumenTAL-3: Phase 3 trial of talquetamab + daratumumab \u00b1 pomalidomide versus daratumumab + pomalidomide + dexamethasone in relapsed\/refractory multiple myeloma following \u22651 prior line of therapy","volume":"140","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"B177","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1182\/blood-2025-701","article-title":"Safety and efficacy of talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma from phase 1b of redirectt-1: Results with an extended median follow-up of 3 years","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1182\/blood-2025-698","article-title":"Efficacy and safety of talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: Updated phase 2 results from the redirectt-1 study with extended follow-up","volume":"146","author":"Usmani","year":"2025","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: A phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","article-title":"MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285185","article-title":"Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma","volume":"110","author":"Othman","year":"2024","journal-title":"Haematologica"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286945","article-title":"Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter\u2019s transformation or transformed non-Hodgkin lymphoma: Results from a phase I trial","volume":"111","author":"Shouse","year":"2025","journal-title":"Haematologica"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"HemaSphere"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005872","article-title":"Pembrolizumab plus dinaciclib in patients with hematologic Malignancies: the phase 1b KEYNOTE-155 study","volume":"6","author":"Gregory","year":"2022","journal-title":"Blood Adv"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf182","article-title":"Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab","volume":"214","author":"Mu","year":"2025","journal-title":"J Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114113","article-title":"Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells","volume":"148","author":"Li","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027616","article-title":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens","volume":"147","author":"Rieger","year":"2025","journal-title":"Blood J"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1002.e1","DOI":"10.1016\/j.jtct.2025.09.003","article-title":"Impact of gamma-secretase inhibition on outcomes following BCMA CAR-T therapy in multiple myeloma: A comparison of two phase 1 trials","volume":"31","author":"Portuguese","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109625","article-title":"PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges","volume":"121","author":"McGowan","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B197","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1177\/09636897241293964","article-title":"CAR-T-cell therapy based on immune checkpoint modulation in the treatment of hematologic Malignancies","volume":"33","author":"Su","year":"2024","journal-title":"Cell Transplant"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168734","article-title":"Nivolumab-based salvage therapy to restore T cell fitness in penta-refractory multiple myeloma with relapse to anti-BCMA CAR T cell therapy","volume":"140","author":"Waldschmidt","year":"2022","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108382","article-title":"Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological Malignancies","volume":"214","author":"Song","year":"2020","journal-title":"Clin Immunol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300475","article-title":"Histone deacetylase inhibitors directly modulate T cell gene expression and signaling and promote development of effector-exhausted T cells in murine tumors","volume":"212","author":"Ibrahim","year":"2024","journal-title":"J Immunol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533044","article-title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","volume":"16","author":"Jo","year":"2025","journal-title":"Front Immunol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","article-title":"CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic Malignancies","volume":"13","author":"Hu","year":"2022","journal-title":"Nat Commun"},{"key":"B206","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","article-title":"Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma","volume":"6","author":"Uribe-Herranz","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014476","article-title":"Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel","volume":"9","author":"Saha","year":"2025","journal-title":"Blood Adv"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice","volume":"106","author":"Bola","year":"2020","journal-title":"Haematologica"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.03.005","article-title":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","volume":"25","author":"Luo","year":"2023","journal-title":"Cytotherapy"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014822","article-title":"Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model","volume":"9","author":"Gamal","year":"2025","journal-title":"Blood Adv"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022682","article-title":"CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models","volume":"144","author":"Brinkmann","year":"2024","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590072","article-title":"HDAC6 inhibition alleviates CLL-induced T-cell dysfunction and enhances immune checkpoint blockade efficacy in the E\u03bc-TCL1 model","volume":"11","author":"Maharaj","year":"2020","journal-title":"Front Immunol"},{"key":"B218","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","article-title":"Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell Malignancies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153612","article-title":"High-throughput CRISPR screening in hematological neoplasms","volume":"14","author":"Ancos-Pintado","year":"2022","journal-title":"Cancers"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010038","article-title":"Gut microbiota and cancer: From pathogenesis to therapy","volume":"11","author":"Vivarelli","year":"2019","journal-title":"Cancers"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031026","article-title":"Gut microbiota influence in hematological Malignancies: From genesis to cure","volume":"22","author":"Uribe-Herranz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B223","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.08.006","article-title":"Microbiome and cancer","volume":"39","author":"Cullin","year":"2021","journal-title":"Cancer Cell"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1456030","article-title":"Metabolic mediators: Microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B228","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cmet.2021.03.002","article-title":"Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity","volume":"33","author":"He","year":"2021","journal-title":"Cell Metab"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","journal-title":"Gut Microbes"},{"key":"B230","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer","volume":"12","author":"Luu","year":"2021","journal-title":"Nat Commun"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma","volume":"30","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1322269111","article-title":"The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition","volume":"111","author":"Chang","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.102947","article-title":"Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases","volume":"285","author":"Singh","year":"2010","journal-title":"J Biol Chem"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"B236","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1038\/s41467-020-16079-x","article-title":"Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer","volume":"11","author":"Coutzac","year":"2020","journal-title":"Nat Commun"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00814","article-title":"Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway","volume":"11","author":"Xu","year":"2020","journal-title":"Front Microbiol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti\u2013programmed death 1 immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B244","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13073-022-01037-7","article-title":"Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort","volume":"14","author":"Newsome","year":"2022","journal-title":"Genome Med"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B246","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32205","article-title":"Microbial translocation augments the function of adoptively transferred self\/tumor-specific CD8+ T cells via TLR4 signaling","volume":"117","author":"Paulos","year":"2007","journal-title":"J Clin Invest"},{"key":"B249","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40168-025-02045-6","article-title":"Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy","volume":"13","author":"Rodr\u00edguez-Garc\u00eda","year":"2025","journal-title":"Microbiome"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000576","article-title":"Influence of gut microbiome on multiple myeloma: friend or foe","volume":"8","author":"Ahmed","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B251","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40168-020-00854-5","article-title":"Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria","volume":"8","author":"Jian","year":"2020","journal-title":"Microbiome"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845422","article-title":"The insider: Impact of the gut microbiota on cancer immunity and response to therapies in multiple myeloma","volume":"13","author":"Brevi","year":"2022","journal-title":"Front Immunol"},{"key":"B253","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.919988","article-title":"Fecal microbiota taxonomic shifts in Chinese multiple myeloma patients analyzed by quantitative polimerase chain reaction (QPCR) and 16S rRNA high-throughput sequencing","volume":"25","author":"Zhang","year":"2019","journal-title":"Med Sci Monit"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1058272","article-title":"Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B256","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/2159-8290.CD-25-1101","article-title":"A high-fiber, plant-based diet in myeloma precursor disorders: Results from the NUTRIVENTION clinical trial and preclinical Vk*MYC model","volume":"16","author":"Shah","year":"2026","journal-title":"Cancer Discov"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0148","article-title":"Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma","volume":"7","author":"Lesokhin","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"B259","doi-asserted-by":"publisher","first-page":"10384","DOI":"10.1038\/s41467-025-65312-y","article-title":"Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma","volume":"16","author":"Cogrossi","year":"2025","journal-title":"Nat Commun"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1362133","article-title":"Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2024","journal-title":"Blood J"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027102","article-title":"Antibiotics: bad bugs for CAR-T cells","volume":"145","author":"Malard","year":"2025","journal-title":"Blood"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566016","article-title":"The impact of antibiotic use on outcomes of relapsed\/refractory multiple myeloma patients treated with CAR-T therapy","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70121","article-title":"Microbiome\u2010based modeling of CAR\u2010T therapy response in lymphoma: Insights from shotgun metagenomics sequencing","volume":"116","author":"Hernani","year":"2026","journal-title":"Eur J Haematol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670286","article-title":"The potential role of the intestinal micromilieu and individual microbes in the immunobiology of chimeric antigen receptor T-cell therapy","volume":"12","author":"Schubert","year":"2021","journal-title":"Front Immunol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1676","article-title":"The potential of the gut microbiota and butyrate to enhance CAR T-cell therapy in non-Hodgkin lymphoma","volume":"32","author":"Garc\u00eda-Vicente","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.19.608538","article-title":"Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells","author":"Staudt","year":"2024","journal-title":"Immunology"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280455","article-title":"The gut microbiome in patients with chronic lymphocytic leukemia","volume":"107","author":"Faitov\u00e1","year":"2022","journal-title":"Haematologica"},{"key":"B269","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3892\/ol.2024.14685","article-title":"Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia","volume":"28","author":"Paziewska","year":"2024","journal-title":"Oncol Lett"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284693","article-title":"The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans","volume":"109","author":"Faitova","year":"2024","journal-title":"Haematologica"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0022","article-title":"Gut microbiome profiling in E\u03bc-TCL1 mice reveals intestinal changes and a dysbiotic signature specific to chronic lymphocytic leukemia","volume":"5","author":"Skupa","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016858","article-title":"Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed\/refractory diffuse large B cell lymphoma","volume":"10","author":"Yoon","year":"2025","journal-title":"Blood Adv"},{"key":"B273","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40164-025-00644-5","article-title":"Immunotherapy in chronic lymphocytic leukemia: advances and challenges","volume":"14","author":"Gao","year":"2025","journal-title":"Exp Hematol Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:51:07Z","timestamp":1781671867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1805129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":273,"alternative-id":["10.3389\/fimmu.2026.1805129"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1805129","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1805129"}}